1 Ferlay, J. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International journal of cancer144, 1941-1953, doi:10.1002/ijc.31937 (2019).
2 Kimura, T. & Egawa, S. Epidemiology of prostate cancer in Asian countries. Int J Urol25, 524-531, doi:10.1111/iju.13593 (2018).
3 Hinotsu, S. et al. Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Japanese journal of clinical oncology37, 775-781, doi:10.1093/jjco/hym098 (2007).
4 Fizazi, K. et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. The New England journal of medicine377, 352-360, doi:10.1056/NEJMoa1704174 (2017).
5 Akaza, H. et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer115, 3437-3445, doi:10.1002/cncr.24395 (2009).
6 Kashiwabara, T. & Suda, S. Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level >/= 50 ng/mL. BMC cancer18, 619, doi:10.1186/s12885-018-4541-0 (2018).
7 Sano, T. et al. Impact of Cardiac Progenitor Cells on Heart Failure and Survival in Single Ventricle Congenital Heart Disease. Circ Res122, 994-1005, doi:10.1161/CIRCRESAHA.117.312311 (2018).
8 Miyoshi, Y. et al. Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases. BMC cancer16, 128, doi:10.1186/s12885-016-2176-6 (2016).
9 Onozawa, M. et al. Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community-based multi-institutional database across Japan using propensity score matching. Cancer Med7, 4893-4902, doi:10.1002/cam4.1735 (2018).
10 Cooperberg, M. R., Hinotsu, S., Namiki, M., Carroll, P. R. & Akaza, H. Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer. BJU international117, 102-109, doi:10.1111/bju.12937 (2016).
11 Shiota, M. et al. Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone. JAMA Netw Open2, e190115, doi:10.1001/jamanetworkopen.2019.0115 (2019).
12 Scher, H. I. et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. Journal of clinical oncology : official journal of the American Society of Clinical Oncology15, 2928-2938, doi:10.1200/JCO.1997.15.8.2928 (1997).
13 Klotz, L. et al. An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study. Prostate Cancer Prostatic Dis17, 320-324, doi:10.1038/pcan.2014.24 (2014).
14 Tombal, B. et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. European urology57, 836-842, doi:10.1016/j.eururo.2009.11.029 (2010).
15 Limonta, P. et al. GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies. Endocr Rev33, 784-811, doi:10.1210/er.2012-1014 (2012).
16 Angelucci, C. et al. GnRH receptor expression in human prostate cancer cells is affected by hormones and growth factors. Endocrine36, 87-97, doi:10.1007/s12020-009-9195-x (2009).
17 Castellon, E. et al. Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma. Cancer Invest24, 261-268, doi:10.1080/07357900600629591 (2006).